Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

STATUS

Recruiting
participants needed

21
sponsor

Shanghai Cell Therapy Group Co.,Ltd

Updated on 19 February 2024

See if I qualify

Summary

Show definitions

This is an open-label, multicenter, dose-escalation phase 1 study to determine the Safety and Efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.

Description

This is an open-label, multicenter, phase 1 study to determine the safety, PK, and antitumor activity of BZ019 in adult subjects with R/R large CD19+B cell lymphoma. The safety and efficacy of a single dose of different target doses of BZ019 will be evaluated in the dose-escalation phase and dose-expansion phase.

Primary objectives:

To evaluate the safety and tolerance of single infusion of BZ019 in adult patients with relapsed or refractory large B-cell lymphoma, and to determine the maximum tolerable dose (MTD) and phase II recommended dose.

Secondary objectives

To evaluate the pharmacokinetics and survival of BZ019 in the peripheral blood of adult patients with relapsed or refractory large B-cell lymphoma;
To evaluate the Pharmacodynamic characteristics of BZ019 in adult patients with relapsed or refractory large B-cell lymphoma;
Objective response rate (ORR), Overall survival, progression free survival, event free survival, and tumor progression time were used to evaluate the antitumor efficacy of BZ019 in the treatment of relapsed or refractory large B-cell lymphoma.

Details

Condition	Large B-cell Lymphoma
Age	18years - 100years
Treatment	BZ019
Clinical Study Identifier	NCT04250324
Sponsor	Shanghai Cell Therapy Group Co.,Ltd
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Written informed consent must be obtained prior to any screening procedures
	Age 18 years subjects with Relapsed or refractory large B-cell lymphoma, only DLBCL non-specific type, primary mediastinal large B-cell lymphoma, follicular lymphoma transformed large B-cell lymphoma, advanced B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, advanced B-cell lymphoma non-specific type. The definition of refractory is as follows
	no response to the last treatment, including:The best response to the latest treatment is disease progression (PD), or the best response to the latest treatment plan is disease stability (SD) and the maintenance time is not more than 6 months after the last administration
	or not suitable for autologous hematopoietic stem cell transplantation (ASCT), or ASCT refractory, including: disease progression after ASCT or recurrence within 12 months (recurrence must be confirmed by biopsy), or if receiving remedial treatment after ASCT, the subject must have no reaction or recurrence after the last treatment
	Subjects must be accepted adequate treatment before and have received at least 2 lines of treatment or relapse or progress after autologous hematopoietic stem cell transplantation, and the treatment history at least include
	Treatment by CD20 monoclonal antibody (Rituximab) except for CD20 negative
	a chemotherapy regimen containing anthracyclines
	According to the preliminary evaluation, staging and response evaluation recommendations for Hodgkin and non Hodgkin's lymphoma (2014 Edition), at least one measurable lesion was found in the screening period
	Life expectancy 12 weeks
	Baseline Eastern Cooperative Oncology Group (ECOG) score is 0 or 1
	Adequate organ function
	Renal function defined as:A serum creatinine of 1.5 x ULN or Estimated Glomerular Filtration Rate (eGFR) 60 mL/min/1.73 m^2
	Liver function defined as:Alanine Aminotransferase (ALT) 5 x ULNBilirubin 2.0 mg/dl with the exception of patients with Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome may be included if their total bilirubin is 3.0 x ULN and direct bilirubin 1.5 x ULN
	Must have a minimum level of pulmonary reserve defined as Grade 1 dyspnea and pulse oxygenation > 91% on room air
	Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) 50%, confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA)
	No blood transfusion within 1 week before signing the informed consent, sufficient bone marrow reserve is available, which is defined as
	Absolute neutrophil count (ANC) > 1000/l
	Absolute lymphocyte count (ALC) 500/l
	Platelets 50000/l
	Hemoglobin > 8.0 g/dl, for patients with bone marrow invasion, hemoglobin > 6.0 g/dl can be considered into the group
	Must have an apheresis product of non-mobilized cells accepted for manufacturing
	If the patient uses the following drugs, the following conditions should be met
	glucocorticoids: The treatment dose of glucocorticoids must be stopped 72 hours before BZ019 infusion. However, glucocorticoids of physiological alternative dose are allowed: prednisone or its equivalent 15 mg / day
	Immunosuppression: Any immunosuppressive medication must be stopped 4 weeks prior to enrollment
	Antiproliferative therapies other than lymphodepleting chemotherapy within two weeks of infusion
	Antibody use including anti-CD20 therapy within 4 weeks prior to infusion or 5 half-lives of the respected antibody, whichever is longer
	CNS disease prophylaxis must be stopped > 1 week prior to BZ019 infusion (e.g. intrathecal methotrexate)
	Women of child-bearing age and all male subjects must agree to use effective contraceptive methods until BZ019 are no longer present in the body (detected by PCR)
Exclusion Criteria
	Patients who have previously received any anti-CD45, anti-CD19 or anti-CD3 therapy
	Patients who have previously received any adoptive T cell therapy or gene therapy products, including CAR-T therapy
	Active Central Nervous System (CNS) involvement by malignancy or secondary CNS involvement
	History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or self-immune disease with CNS involvement
	Prior allogeneic HSCT
	Chemotherapy other than lymphodepleting chemotherapy within 2 weeks of infusion
	Investigational medicinal product within the last 30 days prior to screening
	Prior radiation therapy within 6 weeks of infusion
	Patients with positive hepatitis B (HBsAg and / or HBcAb positive, except for those with positive surface antibody alone) or hepatitis C serological markers
	HIV positive or Treponema pallidum positive patients
	Patients with uncontrollable active or life-threatening bacterial, viral or fungal infection (e.g. blood culture positive 72 hours before infusion)
	Patients with unstable angina and / or myocardial infarction within 6 months before screening, or patients with serious or uncontrollable other diseases (such as unstable or uncompensated respiratory, heart, liver or kidney diseases) during screening
	Previous or concurrent malignancy with the following exceptions
	Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)
	In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study
	A primary malignancy which has been completely resected and in complete remission for 5 years
	Pregnant or nursing (lactating) women
	Patients with uncontrolled arrhythmia
	Patients on oral anticoagulation therapy within 1 week prior to BZ019 infusion
	Patients with active neurological auto immune or inflammatory disorders(e.g. Guillain Barre Syndrome, Amyptrophic Lateral Sclerosis)
	Other protocol-related inclusion/exclusion may apply

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note

Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Sign up as a volunteer to stay informed

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note